Confirming Eligibility for Lutetium Therapy

Key Takeaways

• 68Gallium PSMA-11 PET is preferred for confirming lutetium therapy eligibility due to its high specificity in detecting PSMA expression.
• Alternatives include 18F-DCFPyL PET, which also targets PSMA, offering a viable option when 68Gallium PSMA-11 PET is unavailable.
• Conventional imaging techniques like CT or MRI may be used, but they lack the specificity of PSMA-targeted PET imaging.
• The choice of imaging modality should consider availability, patient-specific factors, and clinical context for accurate assessment.